ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0179

Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies

Lauren Pachman1, Gabrielle Morgan2, Wilfredo Marin3, Sabah Kadri3, Kai Lee Yap3 and Amer Khojah4, 1Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 4Umm Al-Qura University, Makkah, Saudi Arabia

Meeting: ACR Convergence 2022

Keywords: dermatomyositis, Takayasu.s arteritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Muscle Biology, Myositis and Myopathies Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease characterized by proximal weakness and skin rash. Although the exact mechanism of JDM is not clear, the prevailing theory is a combination of environmental triggers and genetic susceptibility. Around 50 % of JDM subjects have a family history of autoimmune diseases such as systemic lupus erythematosus (SLE) and/or type 1 diabetes, suggesting a shared genetic predisposition. Monozygotic twins provide a unique opportunity to examine disease-specific genetic regulation.

Methods: 5 pairs of monozygotic twins were included in this IRB-approved (IRB #2008-13457) study at the Ann and Robert H. Lurie Children’s Hospital of Chicago. Each twin set was discordant for juvenile dermatomyositis. Of note, in one twin pair, both children had developed concordant Mi-2 autoantibody, but only one twin fulfilled the criteria for JDM. We also included 5 age and gender-matched healthy control. Meso Scale Discovery® technique was used to measure the serum level of Interferon gamma-induced protein 10 (IP10) or CXCL10, Monocyte chemotactic protein-3 (MCP3), IL-17d, and angiopoietin 2 (Ang2), and endoglin. Three pairs of twins had their peripheral blood mononuclear cells (PBMCs) tested by RNASeq and one of the pair had whole-genome sequencing (WGS), along with their parents

Results: Three of the 5 sets of monozygotic twins were female. The age ranged from 3.29 years to 13.6 years, with the duration of untreated disease (DUD) ranging from 1.0 months to 11.5 months. As expected, the JDM twin had significantly lower nailfold capillary end row loops (ERL) than the healthy control but, to our surprise, 2 of the non-JDM twins had decreased ERL as well. The serum endoglin was significantly lower in both JDM-twins and non-JDM twins than in the healthy control. Other cytokines did not differ significantly which could be due to the small sample size. The RNASeq of 3 pairs of twins identified 4 genes that were differentially expressed between the JDM twins (case) compared with the non-JDM twins (control). These genes are Dermcidin (DCD), Keratin 14 (KRT14), Collagen Type I Alpha 1 Chain (COL1A1), and Collagen Type III Alpha 1 Chain (COL3A1). WGS did not identify any clinically significant variants that could be potentially related to their JDM phenotype

Conclusion: Monozygotic twins provide a unique opportunity to assess differential gene expression. The JDM twins had higher mRNA expression of DCD, KRT14, COL1A1, and COL3A1 than non-JDM twins. DCD and KRT14 are associated with other rare hereditary skin diseases such as Netherton Syndrome and epidermolysis bullosa simplex control. Both genes are almost exclusively expressed in skin tissue in healthy individuals. Therefore, the increased expression could be due to the presence of damaged skin cells in the circulation or represent a clue concerning an unknown disease process related to JDM. Soluble endoglin, an antiangiogenic molecule that binds to TGF-β, was lower in both the JDM twin and the healthy twin control which could suggest increased angiogenesis due to vascular damage, as manifest by loss of nailfold ER in both the JDM twin and their presumably healthy twin control.


Disclosures: L. Pachman, None; G. Morgan, None; W. Marin, None; S. Kadri, AbbVie/Abbott; K. Yap, None; A. Khojah, None.

To cite this abstract in AMA style:

Pachman L, Morgan G, Marin W, Kadri S, Yap K, Khojah A. Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/discordant-monozygotic-twins-with-juvenile-dermatomyositis-genetic-and-clinical-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discordant-monozygotic-twins-with-juvenile-dermatomyositis-genetic-and-clinical-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology